Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Share

Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common share equivalents):

	Years Ended December 31,
	2022		2021		2020
Common stock warrants		13,760		13,760		13,904
Common stock options and restricted stock units		3,077,608		1,420,050		584,211
Employee stock purchase plan		34,588		2,045		1,602
Total		3,125,956		1,435,855		599,717

Summary of Net Loss Per Share

The following table summarizes our net loss per share (in thousands, except per share data):

	Years Ended December 31,
	2022			2021			2020
Numerator:
Net loss attributable to aTyr Pharma, Inc.	$	(45,338	)	$	(33,768	)	$	(16,224	)
Denominator:
Weighted average common shares outstanding		28,419,569			19,080,878			9,160,269
Weighted average common shares subject to repurchase		—			—			—
Shares used in computing net loss per share, basic and diluted		28,419,569			19,080,878			9,160,269
Net loss per share - basic and diluted	$	(1.60	)	$	(1.77	)	$	(1.77	)